Oxiracetam In The Treatment Of Multi-infarct Dementia And Primary Degenerative Dementia
| Effect | Increase |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 73 |
| Sex | Both Genders |
| Age Range | 65+ |
In persons with primary or multiinfarct dementia supplemented with oxiracetam, there appeared to be a significant reduction in symptoms of cognitive decline with particular improvement of verbal learning (word fluency) although a functional assessment (Instrumental Activities of Daily Living Scale) showed no significant changes.
